Information about Zafirlukast
Generic Name : ZafirlukastUp-to-date prescription details regarding Zafirlukast are provided here.
Pronunciation : ZA-fir-LOO-kast
Learn the correct pronunciation of the Zafirlukast, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.
ICD Code : Y55.6 Therapeutic Classification : Anti- Asthmatics
Trade Names/Brand Names of Zafirlukast
India :
International :
Accolate
Why is Zafirlukast Prescribed? (Indications)
This medication is an oral leukotriene receptor antagonist (LTRA), prescribed for asthma. It blocks the action of certain natural substances that cause swelling and tightening of the airways.When should Zafirlukast not be taken? (Contraindications)
Hypersensitivity.What is the dosage of Zafirlukast?
Adult- The recommended dose is 20 mg twice daily.Child- The recommended dose is 10 mg twice daily.
How should Zafirlukast be taken?
It comes as a tablet to take by mouth, with food.What are the warnings and precautions for Zafirlukast?
• Caution should be exercised in patients with history of liver disease, mental problems, suicidal thoughts, any allergy, elderly, during pregnancy and breastfeeding.• Avoid decreasing the dosage without doctor’s advice.
• Continue the use of inhalers if you have used it before the treatment.
• Patient may develop with increased risk of liver problems; monitor liver functions regularly.
What are the side effects of Zafirlukast?
Central Nervous System- Headache, weakness and dizziness.Gastrointestinal- Nausea, vomiting, diarrhea, abdominal pain and indigestion.
Miscellaneous- Infection, generalized pain, muscle pain, fever, back pain and elevation in liver enzymes.
